Results 61 to 70 of about 24,414 (214)

Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats

Acta Pharmacologica Sinica, 2020
Hyperlipidemia (HPL) characterized by metabolic disorder of lipids and cholesterol is one of the important risk factors for cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a potent circulating regulator of LDL through ...
Zhen-li Su, Peng-zhou Hang, Juan Hu, Yu-yang Zheng, Han-qi Sun, Jing Guo, Ke Liu, Zhimin Du   +7 more
semanticscholar   +1 more source

Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea

Türk Biyokimya Dergisi
We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA).
Deniz Levent, Aral Hale, Akdoğan Özlem, Arslan Hilmi Furkan, Yiğit Enes   +4 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Frontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu, En Li, Xiaoyu Yang, Xiaoyu Yang   +3 more
doaj   +1 more source

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis

Journal of Community Hospital Internal Medicine Perspectives, 2020
Background Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunction in patients with or without previous liver injury, and this is not well discussed in the previous literature.
Yousuf Zafar, Yasar Sattar, Waqas Ullah, Sohaib Roomi, Mamoon-Ur- Rashid, Muhammad Shayan Khan, Laura Schmidt   +6 more
doaj   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9 [PDF]

Journal of Thoracic Disease, 2017
Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood low-density lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed.
Kazuhiko, Kotani, Maciej, Banach
openaire   +2 more sources

Secretome Analysis of Cardiomyocytes Identifies PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6) as a Novel Player in Cardiac Remodeling After Myocardial Infarction

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Acute occlusion of a coronary artery results in swift tissue necrosis. Bordering areas of the infarcted myocardium can also experience impaired blood supply and reduced oxygen delivery ...
T. Kuhn, J. Knobel, Sonja Burkert-Rettenmaier, Xue Li, I. S. Meyer, A. Jungmann, Florian Sicklinger, J. Backs, F. Lasitschka, O. Müller, H. Katus, J. Krijgsveld, F. Leuschner   +12 more
semanticscholar   +1 more source

Vascular Calcification: Mechanisms, Models, and Therapies

iNew Medicine, EarlyView.
ABSTRACT Vascular calcification represents an active multifactorial process that mirrors several key features of skeletal bone mineralization. Clinically, it is characterized by diminished arterial compliance and increased arterial wall stiffness, both of which serve as independent predictors of significant adverse cardiovascular events.
Wenya Zhu, Shu Yang, Ziyi Chen, Xiaoxiao Yang, Zhen Liang, Yuanli Chen   +5 more
wiley   +1 more source

Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9

International Journal of Biomedical Investigation, 2020
High levels of cholesterol, especially as low-density lipoprotein (LDL), are a well-known risk factor for atherosclerotic-related diseases. The key atherogenic property of LDL is its ability to form atherosclerotic plaque. Proprotein convertase subtilisin/kexin-9 (PCSK9) is an indirect regulator of plasma LDL levels by controlling the number of LDL ...
Melendez, Quantil M., Wooten, Catherine J., Krishnaji, Sreevidhya T., Knagge, Kevin, Kirchner, David, Lopez, Dayami   +5 more
openaire   +2 more sources

Expanding the genotypic spectrum of PCSK1 deficiency: A novel mutation in severe neonatal diarrhea

JPGN Reports, EarlyView.
Abstract Among congenital diarrhea and enteropathies (CODEs), proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency is a rare monogenic disorder, associated with severe neonatal diarrhea and polyendocrinopathies. We report an 18‐day‐old male neonate, born to consanguineous parents, presenting with persistent watery diarrhea, metabolic ...
Eleonora Saraceno, Angelo Corso Faini, Silvia Deaglio, Marianna Pellegrini, Raffaele Buganza, Francesca Giuliani, Pier Luigi Calvo, Michele Pinon   +7 more
wiley   +1 more source